Psychobiotics, a class of probiotics and prebiotics that influence the microbiota–gut–brain axis (MGBA), have emerged as a promising area of research in understanding the relationship between gut health and mental wellness. Recent studies highlight that the gut microbiome plays a crucial role in regulating neurological and psychological functions through neural, endocrine, immune, and metabolic pathways. The gut produces a significant proportion of key neurotransmitters such as serotonin and dopamine, and imbalances in gut microbial composition have been associated with mental health disorders including depression, anxiety, and cognitive decline. Psychobiotics exert their effects through multiple mechanisms, including the production of neurotransmitters such as GABA, serotonin, and dopamine; reduction of systemic inflammation; regulation of the hypothalamic–pituitary–adrenal (HPA) axis to manage stress responses; and epigenetic modulation through short-chain fatty acids that promote neuroplasticity. Evidence from animal models and human clinical trials demonstrates that specific probiotic strains, such as Lactobacillus and Bifidobacterium, may reduce psychological distress, improve mood, lower cortisol levels, and enhance cognitive functions. Alterations in the gut microbiome have also been observed in individuals with major depressive disorder (MDD), suggesting a potential therapeutic role for psychobiotics in mental health management. Emerging research is exploring novel microbial strains and personalized psychobiotic therapies enabled by advancements in genomic technologies. However, limitations remain, including small sample sizes, methodological inconsistencies, uncertain long-term effects, and potential risks for immunocompromised individuals. Despite these challenges, psychobiotics represent a promising adjunctive approach in the prevention and management of mental health disorders by targeting the gut–brain connection.
Shiny Deborah Rani Kankipati (Mon,) studied this question.